azomycin has been researched along with irinotecan in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y | 1 |
Bernards, N; De Souza, R; Fitzgerald, JB; Fricke, IB; Hendriks, BS; Klinz, SG; Lee, H; Ventura, M; Zheng, J | 1 |
2 other study(ies) available for azomycin and irinotecan
Article | Year |
---|---|
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia.
Topics: Animals; Cell Hypoxia; Female; Fluorine Radioisotopes; Irinotecan; Liposomes; Longitudinal Studies; Mice; Mice, Inbred NOD; Mice, SCID; Nitroimidazoles; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |